| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1990.8.4.705 |
| P698 | PubMed publication ID | 2179481 |
| P50 | author | Georges Mathé | Q1438399 |
| P2093 | author name string | M Benavides | |
| F Lévi | |||
| J L Misset | |||
| A Reinberg | |||
| F Bailleul | |||
| J M Vannetzel | |||
| C Chevelle | |||
| C Regensberg | |||
| F Le Saunier | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| ovarian cancer | Q172341 | ||
| circadian rhythm | Q208353 | ||
| cisplatin | Q412415 | ||
| chemotherapy | Q974135 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 705-714 | |
| P577 | publication date | 1990-04-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity | |
| P478 | volume | 8 |
| Q73923794 | A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer |
| Q73694646 | A phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancer |
| Q50031930 | A randomized phase II trial of induction chemotherapy followed by cisplatin chronotherapy versus constant rate delivery combined with radiotherapy |
| Q41552408 | Activity of anthracyclines in refractory ovarian cancer: recent experience and review |
| Q36710027 | Cancer chronomics II. Origins of timing cancer treatment. |
| Q33742395 | Cancer chronotherapy |
| Q35030286 | Cancer chronotherapy: principles, applications, and perspectives |
| Q30914834 | Chronomodulated chemotherapy versus conventional chemotherapy for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. |
| Q100472612 | Circadian Variation in Efficacy of Medications |
| Q34606499 | Circadian chemotherapy for gynecological and genitourinary cancers |
| Q34572050 | Circadian chronotherapy for human cancers |
| Q24602881 | Circadian clock control of the cellular response to DNA damage |
| Q35081714 | Circadian function in cancer: regulating the DNA damage response. |
| Q39772578 | Circadian time-dependent tumor suppressor function of period genes |
| Q88595919 | Cisplatin-DNA adduct repair of transcribed genes is controlled by two circadian programs in mouse tissues |
| Q35994324 | DNA cell cycle distribution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients |
| Q41455278 | Developing circadian rhythmicity. Basic and clinical aspects |
| Q53299729 | It is time for chronotherapy! |
| Q53317449 | It's time for chronotherapy! |
| Q38864988 | Late chronotypes are associated with neoadjuvant chemotherapy-induced nausea and vomiting in women with breast cancer |
| Q37965990 | Making a case for programmable pumps over fixed rate pumps for the management of fluctuations in chronic pain and spasticity: a literature review. |
| Q43965417 | Marker rhythms of circadian system function: a study of patients with metastatic colorectal cancer and good performance status. |
| Q33262921 | Modeling biological rhythms in failure time data |
| Q33834597 | Oxaliplatin: pharmacokinetics and chronopharmacological aspects |
| Q54218013 | Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer. |
| Q34168873 | Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer |
| Q35756234 | Stimuli-sensitive hydrogels: ideal carriers for chronobiology and chronotherapy |
| Q96303179 | The circadian clock gene Bmal1 facilitates cisplatin-induced renal injury and hepatization |
| Q35143947 | Toxicity of platinum compounds |
| Q28077467 | WOMEN IN CANCER THEMATIC REVIEW: Circadian rhythmicity and the influence of 'clock' genes on prostate cancer |
Search more.